Table 2.
Factors associated with the virological response after MCT in all the study subjectsa
| Characteristic | Value of characteristic by treatment responseb |
Bivariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|---|
| MCT positive (n = 65) | MCT negative (n = 25) | P | OR (95% CI)c | P | OR (95% CI) | |
| No. of males/total no. (%) | 50/65 (77) | 21/25 (84) | 0.464 | 0.635 (0.188–2.140) | NAd | |
| Age (yr) | 42 (35–46) | 43 (37–47) | 0.677 | 1.009 (0.967–1.054) | NA | |
| No. treatment naïve/total no. (%) | 18/65 (28) | 1/25 (4) | 0.036 | 9.191 (1.157–73.048) | 0.283 | 3.857 (0.328–45.364) |
| No. infected by sexual transmission/total no. (%) | 40/65 (62) | 7/25 (28) | 0.006 | 4.114 (1.505–11.250) | 0.406 | 1.767 (0.462–6.765) |
| No. infected by IDUe transmission/total no. (%) | 22/65 (34) | 13/25 (52) | 0.117 | 0.472 (0.185–1.206) | NA | |
| Time since diagnosis (yr) | 12 (2–19) | 16 (12–19) | 0.068 | 0.944 (0.888–1.004) | 0.890 | 1.007 (0.911–1.114) |
| No. HCV PCR+f/total no. (%) | 22/65 (34) | 9/25 (36) | 0.847 | 0.910 (0.347–2.387) | NA | |
| CD4+ count (cells/ml) | 355 (226–465) | 149 (21–320) | 0.001 | 1.006 (1.002–1.009) | 0.011 | 1.004 (1.001–1.008) |
| Plasma log VL (HIV RNA copies/ml) | 4.4 (3.7–4.9) | 4.6 (3.5–5.2) | 0.557 | 0.861 (0.521–1.421) | NA | |
a
Data are for 90 subjects. Bivariate and multivariate analyses were performed using a logistic regression model, and variables showing a P value of <0.1 (boldface) in the bivariate analysis were included in the multivariate analysis. In the multivariate analysis, variables with a P value of <0.05 (boldface) were considered statistically significant.
b
Values other than number (percent) are expressed as medians (interquartile ranges).
c
OR, odds ratio; CI, confidence interval.
d
NA, not applicable.
e
IDU, injecting drug user.
f
PCR+, PCR positive for hepatitis C virus.